Please login to the form below

Not currently logged in
Email:
Password:

abiraterone acetate

This page shows the latest abiraterone acetate news and features for those working in and with pharma, biotech and healthcare.

EMA starts review of Xtandi in non-metastatic prostate cancer

EMA starts review of Xtandi in non-metastatic prostate cancer

At the moment Xtandi - like longstanding rival Zytiga (abiraterone acetate) from Johnson &Johnson - is only prescribed for men with advanced CRPC that has spread and no longer responds to hormone therapy.

Latest news

More from news
Approximately 2 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2013 Pharma deals during October 2013

    AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy

  • Interview: Cesar Rodriguez, Janssen Interview: Cesar Rodriguez, Janssen

    Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “ a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics